Measures autoantibodies against the CXCR3 chemokine receptor, which is found on activated immune cells. The test helps evaluate immune dysregulation in suspected autoimmune disorders.
CXCR3-Ak is often considered in the context of tiredness, reduced capacity, brain fog, or chronic exhaustion. This short overview clarifies what the marker can contribute, where its limits are, and when symptom or illness context becomes more important.
CXCR3-Ak becomes relevant when low-grade inflammation, immune activity, or recovery questions are part of the picture. It can help flag inflammatory context, but it does not map symptom severity on its own.
CXCR3-Ak does not explain PEM, delayed worsening after activity, unstable day-to-day function, or a wider multisystem pattern on its own. A single lab value can support interpretation, but it cannot replace symptom timing and longitudinal context.
If fatigue persists, exertion is tolerated poorly, or symptoms escalate after activity, the marker should be linked to a broader fatigue, ME/CFS, PEM, or questionnaire context. That usually makes interpretation far more useful than treating the value as a standalone endpoint.
CXCR3 antibodies are autoantibodies that target the CXCR3 receptor, a protein expressed on the surface of activated T cells and natural killer cells. This receptor plays a role in directing immune cell movement. The presence of these antibodies can disrupt normal immune regulation and has been associated with autoimmune conditions such as Sjögren’s syndrome and systemic lupus erythematosus (SLE). Testing for CXCR3 antibodies is typically performed as part of an immunological workup when an autoimmune disorder is suspected.
The reference range for CXCR3 antibodies is typically negative (lab-dependent). A result below the detection threshold (i.e., a negative result) is considered normal and suggests no significant level of autoantibodies against the CXCR3 receptor.
A positive result (above the lab-specific cutoff) indicates the presence of CXCR3 autoantibodies. This may suggest an underlying autoimmune process affecting immune function. CXCR3 antibodies have been observed in conditions like Sjögren’s syndrome, systemic lupus erythematosus, and other connective tissue diseases. However, a positive result alone is not diagnostic and should be interpreted alongside clinical findings and other laboratory tests.
This result is not specific for ME/CFS or Long COVID. Read it together with the clinical question, symptoms, related findings and the laboratory reference range rather than in isolation.
Practical details are separated from the general FAQ so they are easier to find.
CXCR3-Ak becomes relevant when low-grade inflammation, immune activity, or recovery questions are part of the picture. It can help flag inflammatory context, but it does not map symptom severity on its own.
If fatigue persists, exertion is tolerated poorly, or symptoms escalate after activity, the marker should be linked to a broader fatigue, ME/CFS, PEM, or questionnaire context. That usually makes interpretation far more useful than treating the value as a standalone endpoint.
You now know which questions can matter when reading this result. With Elara you can keep the value and its surrounding context together over time.
Save the lab value with its date so individual measurements do not get lost.
See previous measurements together instead of relying on a single snapshot.
View CXCR3 Antibody (Anti-CXCR3) alongside symptom, energy, sleep and PEM entries without assuming one caused the other.
Export your history as a PDF — structured for the next check-up.
CXCR3 antibody tests are usually qualitative, meaning the result is reported as either negative or positive. A negative result is considered normal, indicating that autoantibodies against CXCR3 were not detected. Reference standards are lab-dependent.
A positive CXCR3 antibody test suggests the presence of autoantibodies that may be involved in immune dysregulation. It has been linked to autoimmune diseases such as Sjögren’s syndrome and systemic lupus erythematosus (SLE). However, the test is not widely used in routine clinical practice, and results should be discussed with a specialist.
Research has found CXCR3 antibodies in patients with Sjögren’s syndrome, systemic lupus erythematosus, and possibly other autoimmune disorders. The marker is considered exploratory, and its exact role in disease is still under investigation.
CXCR3-Ak does not explain PEM, delayed worsening after activity, unstable day-to-day function, or a wider multisystem pattern on its own. A single lab value can support interpretation, but it cannot replace symptom timing and longitudinal context.
For many fatigue-related, inflammatory, hormonal, or recovery-linked markers, interpretation becomes stronger when symptoms, exertion response, and daily function are considered together.
CXCR3-Ak is rarely meaningful in isolation when fatigue, brain fog, or unstable capacity are central. The fatigue hub provides the broader lab-and-symptom context.
If symptoms worsen after activity with a delay, PEM often explains more than an isolated lab value alone.
Questionnaires help connect biomarkers to symptom patterns, functional limits, and patient-reported change over time.
Markers from the same system can add useful context when a single lab value is hard to interpret on its own.
No individual medical review is documented.
This English content was created with AI assistance and automatically validated. This is not an individual medical review.
This information does not replace medical advice. Lab values should be assessed in the context of your medical history, the reason for testing and other findings. Elara provides health information for orientation — not diagnoses or treatment decisions.
Bring your lab values, symptoms and energy into one shared context — so you walk into your next appointment more informed and structured.
